Status:
COMPLETED
Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborating Sponsors:
American Cancer Society, Inc.
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this proposal will v...
Detailed Description
The investigators plan to use a novel antibody developed at Dartmouth-Hitchcock Medical Center to characterize the expression of LPL in CLL. Peripheral blood from CLL patients will be analyzed by flow...
Eligibility Criteria
Inclusion
- Diagnosis of CLL as per National Cancer Institute Working Group Guidelines
- Patients undergoing routine blood draws as part of their ongoing follow up for CLL
- 18 years or older
- Ability to provide consent in English
- Patient must have measurable disease as defined by an absolute lymphocyte count greater than 5,000/mm3 or have archived lymph node or bone marrow with CLL involvement.
Exclusion
- Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for their CLL,
- other hematologic malignancy or other disease process within the past 6 months are excluded.
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2018
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT01460238
Start Date
October 1 2011
End Date
May 1 2018
Last Update
March 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756